ÂÜÀòÂÒÂ×

Alan Colowick, MD, currently serves on the Board of Directors of Personalis, Harpoon Therapeutics, and InCarda. He was recently Chairman of the Board of Principia (acquired by Sanofi) and VelosBio (acquired by Merck).

Dr. Colowick is a former partner at Sofinnova Ventures. Before joining Sofinnova, he held executive management and board of director positions at numerous companies in the biotechnology sector. Most recently, he was Executive Vice President at Celgene Corporation, and prior to that held positions of President for Celgene’s Europe, Mid‑East, and Africa regions as well as Senior Vice President of Global Medical Affairs. Previously, Dr. Colowick was the Chief Executive Officer at Gloucester Pharmaceuticals, Inc. until its acquisition by Celgene in 2010. Before becoming CEO at Gloucester Pharmaceuticals, he was President, Oncology for Geron Corporation and was Chief Medical Office of Threshold Pharmaceuticals. Prior to that, Dr. Colowick held numerous positions of increasing responsibility at Amgen Inc culminating with his role as VP, Medical Affairs Europe.

Dr. Colowick received an MD from Stanford University and an MPH from Harvard University. Additionally, he completed specialty training in Hematology-Oncology at the Dana Farber Cancer Institute and Brigham and Women’s Hospital. He has a BS in Molecular Biology from the University of Colorado.